Overall survival (OS) in METEOR, a randomized phase 3 trial of cabozantinib (Cabo) versus everolimus (Eve) in patients (pts) with advanced renal cell carcinoma (RCC) Meeting Abstract
| Authors: | Choueiri, T. K.; Powles, T.; Escudier, B. J.; Tannir, N. M.; Mainwaring, P.; Rini, B. I.; Hammers, H. J.; Donskov, F.; Roth, B. J.; Peltola, K.; Lee, J. L.; Heng, D. Y. C.; Schmidinger, M.; Aftab, D. T.; Hessel, C.; Scheffold, C.; Schwab, G.; Pal, S. K.; Hutson, T. E.; Motzer, R. J. |
| Abstract Title: | Overall survival (OS) in METEOR, a randomized phase 3 trial of cabozantinib (Cabo) versus everolimus (Eve) in patients (pts) with advanced renal cell carcinoma (RCC) |
| Meeting Title: | 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 34 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2016 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2016-05-20 |
| Start Page: | 245s |
| Language: | English |
| ACCESSION: | WOS:000404665407079 |
| DOI: | 10.1200/JCO.2016.34.15_suppl.4506 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 4506 -- Source: Wos |
